← Back to Clinical Trials
Recruiting NCT07522736

NCT07522736 Intrathecal Dexmedetomidine With Bupivacaine, in Patients Undergoing Knee Orthopedic Surgery

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07522736
Status Recruiting
Phase
Sponsor Cairo University
Condition Intrathecal Dexmedetomidine
Study Type INTERVENTIONAL
Enrollment 120 participants
Start Date 2025-03-01
Primary Completion 2026-08-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Dexmedetomidine 4 μgDexmedetomidine 8 μgDexmedetomidine 12 μg

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 120 participants in total. It began in 2025-03-01 with a primary completion date of 2026-08-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to compare the duration of analgesia (as the primary outcome) and adverse effects (as the secondary outcome) after intrathecal administration of dexmedetomidine with hyperbaric bupivacaine to patients undergoing knee orthopedic surgery.

Eligibility Criteria

Inclusion Criteria: * Age from 18 to 65 years. * American Society of Anesthesiologists (ASA) physical status I-II. * Male patients scheduled for knee orthopedic surgery. Exclusion Criteria: * Patients with psychiatric disorders. * History of drug addiction. * Contraindication for regional anesthesia. * History of hypersensitivity to the study drugs. * Previous administration of opioids and/or other central nervous system depressants during current hospital admission.

Contact & Investigator

Central Contact

Ahmed A Ismail, MSc

✉ ahmed.ali39348@postgrad.kasralainy.edu.eg

📞 00201115746779

Frequently Asked Questions

Who can join the NCT07522736 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Intrathecal Dexmedetomidine. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07522736 currently recruiting?

Yes, NCT07522736 is actively recruiting participants. Contact the research team at ahmed.ali39348@postgrad.kasralainy.edu.eg for enrollment information.

Where is the NCT07522736 trial being conducted?

This trial is being conducted at Cairo, Egypt.

Who is sponsoring the NCT07522736 clinical trial?

NCT07522736 is sponsored by Cairo University. The trial plans to enroll 120 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology